See also separate entry for meropenem.
- TRADE NAME: Vabomere (Rempex)
- INDICATIONS: Complicated urinary tract infections caused by susceptible bacteria
- CLASS: Antibiotic, Antibiotic; carbapenem (meropenem), Antimicrobial, Beta-lactamase inhibitor (vaborbactam)
- HALF-LIFE: 1–2 hours
- FDA APPROVAL DATE: 08/29/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Probenecid, Valproic Acid - PREGNANCY: Potential risk to fetus based on animal studies
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
